ADMP vs. INFI, NRSN, CMMB, CMRA, SHPH, NMTR, GOVX, AKTX, AVTX, and LCI
Should you be buying Adamis Pharmaceuticals stock or one of its competitors? The main competitors of Adamis Pharmaceuticals include Infinity Pharmaceuticals (INFI), NeuroSense Therapeutics (NRSN), Chemomab Therapeutics (CMMB), Comera Life Sciences (CMRA), Shuttle Pharmaceuticals (SHPH), 9 Meters Biopharma (NMTR), GeoVax Labs (GOVX), Akari Therapeutics (AKTX), Avalo Therapeutics (AVTX), and Lannett (LCI). These companies are all part of the "pharmaceutical preparations" industry.
Adamis Pharmaceuticals vs.
Infinity Pharmaceuticals (NASDAQ:INFI) and Adamis Pharmaceuticals (NASDAQ:ADMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.
Infinity Pharmaceuticals presently has a consensus price target of $2.83, suggesting a potential upside of 1,411.11%. Given Infinity Pharmaceuticals' higher possible upside, equities analysts clearly believe Infinity Pharmaceuticals is more favorable than Adamis Pharmaceuticals.
Adamis Pharmaceuticals has a net margin of -556.71% compared to Infinity Pharmaceuticals' net margin of -1,870.85%. Adamis Pharmaceuticals' return on equity of -420.53% beat Infinity Pharmaceuticals' return on equity.
Infinity Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Adamis Pharmaceuticals has higher revenue and earnings than Infinity Pharmaceuticals.
In the previous week, Infinity Pharmaceuticals had 4 more articles in the media than Adamis Pharmaceuticals. MarketBeat recorded 8 mentions for Infinity Pharmaceuticals and 4 mentions for Adamis Pharmaceuticals. Adamis Pharmaceuticals' average media sentiment score of 0.63 beat Infinity Pharmaceuticals' score of 0.55 indicating that Adamis Pharmaceuticals is being referred to more favorably in the news media.
Infinity Pharmaceuticals received 48 more outperform votes than Adamis Pharmaceuticals when rated by MarketBeat users. However, 67.34% of users gave Adamis Pharmaceuticals an outperform vote while only 56.43% of users gave Infinity Pharmaceuticals an outperform vote.
34.6% of Infinity Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Adamis Pharmaceuticals shares are held by institutional investors. 9.8% of Infinity Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of Adamis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Infinity Pharmaceuticals beats Adamis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adamis Pharmaceuticals Competitors List
